-
BRL44385
- names:
BRL44385
- CAS號(hào):
114778-60-8
MDL Number: MFCD00871933 - MF(分子式): C8H11N5O3 MW(分子量): 225.2
- EINECS: Reaxys Number:
- Pubchem ID:135409371 Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (¥) | 現(xiàn)價(jià)(¥) | 特價(jià)(¥) | 庫存描述 | 數(shù)量 | 總計(jì) (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000724-5mg | 5mg | ¥ 20553.00 | ¥ 20553.00 | Backorder | ¥ 0.00 | |||
| YZM000724-1mg | 1mg | >97% | ¥ 9945.00 | ¥ 9945.00 | 2-3天 | ¥ 0.00 |
- 大包裝詢價(jià) 提供各種包裝,敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購物車 立即購買
| 中文別名 | BRL44385(114778-60-8);9-(3-羥基丙氧基)鳥嘌呤;BRL 44385;BRL-44385; |
| 英文別名 | BRL44385(114778-60-8);9-(3-hydroxypropoxy)guanine;BRL 44385;BRL-44385; |
| CAS號(hào) | 114778-60-8 |
| Inchi | InChI = 1S / C8H11N5O3 / c9-8-11-6-5(7(15)12-8)10-4-13(6)16-3-1-2-14 / h4,14H,1-3H2, (H3,9,11,12,15) |
| InchiKey | UWCACOXRVYDNEE-UHFFFAOYSA-N |
| 分子式 Formula | C8H11N5O3 |
| 分子量 Molecular Weight | 225.2 |
| 溶解度Solubility | |
| 性狀 | Solid |
| 儲(chǔ)藏條件 Storage conditions | 存放在陰涼干燥處 |
BRL44385(114778-60-8)實(shí)驗(yàn)注意事項(xiàng):
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡,穿戴防護(hù)服和口罩,佩戴手套,避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生,必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ),并交于專業(yè)生物廢氣物處理公司處理,以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:BRL44385,BRL44385,BRL44385,BRL44385,BRL44385,BRL44385,BRL44385,BRL44385,BRL44385,BRL44385,
| 產(chǎn)品說明 | BRL44385(114778-60-8)是一種新型鳥嘌呤類似物,是1型和2型單純皰疹病毒和水痘帶狀皰疹病毒的有效和選擇性抑制劑。 |
| Introduction | BRL44385(114778-60-8)is a potent and selective inhibitor of the replication of herpes simplex virus types 1 and 2 (HSVandHSV2), varicella zoster virus (VZV) and Epsteinarr virus (EBV). |
| Application1 | |
| Application2 | |
| Application3 |
BRL44385(114778-60-8)藥理學(xué):
BRL44385是一種新型鳥嘌呤類似物,是1型和2型單純皰疹病毒和水痘帶狀皰疹病毒的有效和選擇性抑制劑。
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡(如果有)并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過程中防止吸入、食入,做好安全防護(hù) |
| M. R. Harnden, et al. Synthesis, oral bioavailability and in vivo activity of acetal derivatives of the selective antiherpesvirus agent 9-(3-hydroxypropoxy) guanine (SRL 44385). Antiviral Chemistry & |
| Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent PMID 8013273; Drug metabolism and disposition: the biological |
| Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells Antimicrobial agents and chemotherapy8723485 1996-05-01 |
| Synthesis and antiviral activity of 9-alkoxypurines. 1. 9-(3-Hydroxypropoxy)- and 9-[3-hydroxymethyl)propoxy]purines Journal of medicinal chemistry2153202 1990-01-01 |
BRL44385(114778-60-8)參考文獻(xiàn):
1.Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent.
Harrell AW;Wheeler SM;East P;Clarke SE;Chenery RJ Drug Metab Dispos. 1994 Mar-Apr;22(2):189-93.
BRL 55792, BRL 55791, and BRL 55039 are prodrugs of an active antiviral agent 9-(3-hydroxypropoxy) guanine (BRL 44385). The prodrugs were 6-deoxygenated analogs of BRL 44385, with ether groups substituted at the 9-position: BRL 55792 with an (isopropoxymethyloxy)propoxy group, BRL 55791 with a (methoxymethyloxy)propoxy group, and BRL 55039 with an ethoxypropoxy group. Conversion of the prodrugs to BRL 44385 had been demonstrated in vivo in the rat and involved 6-oxidation followed by dealkylation. Metabolism was studied in rat liver in vitro systems to find a model to evaluate BRL 44385 production. Rat hepatocytes performed both reaction steps and were used to assess which of the three prodrugs demonstrated greatest production of the active drug. BRL 55792 demonstrated greatest conversion in vitro, and this was in agreement with in vivo data. The production of BRL 44385 from BRL 55792 was also demonstrated in human hepatocyte incubations, providing evidence that these reactions can occur in humans, thereby increasing confidence that BRL 55792 would be suitable prodrug for human therapy. Further experiments were performed to investigate the enzymes involved in these conversions. The 6-oxidation step occurred in the cytosol.
2.Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxy-guanine analogues as prodrugs of an antiviral agent.
Harrell AW;Wheeler SM;East P;Clarke SE;Chenery RJ Drug Metab Dispos. 1994 Jan-Feb;22(1):124-8.
BRL 55792, BRL 55791, and BRL 55039 are prodrugs of an active anti-viral agent 9-(3-hydroxypropoxy) guanine, (BRL 44385). The prodrugs were 6-deoxygenated analogues of BRL 44385 with ether groups substituted at the 9-position: BRL 55792 with an (isopropoxymethyloxy)propoxy group, BRL 55791 with a (methoxymethyloxy)propoxy group, and BRL 55039 with an ethoxypropoxy group. Conversion of the prodrugs to BRL 44385 had been demonstrated in vivo in rat and involved 6-oxidation followed by dealkylation. Metabolism was studied in rat liver in vitro systems to find a model to evaluate BRL 44385 production. Rat hepatocytes performed both reaction steps and were used to assess which of the three prodrugs demonstrated greatest production of the active drug. BRL 55792 demonstrated greatest conversion in vitro and this was in agreement with in vivo data. The production of BRL 44385 from BRL 55792 was also demonstrated in human hepatocyte incubations providing evidence that these reactions can occur in man thereby increasing confidence that BRL 55792 would be a suitable prodrug for human therapy. Further experiments were performed to investigate the enzymes involved in these conversions. The 6-oxidation step occurred in the cytosol.
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色,是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi),細(xì)胞在玻片上生長,主要用于組織學(xué),免疫組織化學(xué)...
2020/7/20 22:04:33

提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26

9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55

Waxfilm 實(shí)驗(yàn)室封口膜:技術(shù)與國際市場的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域,封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來,Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40

Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07

各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09

新一代微流控鍵合解決方案
微流控鍵合解決方案:微流控芯片制造的一個(gè)重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是:微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說明
D-熒光素鉀鹽(K+)設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11

如何選BSA(牛血清白蛋白)
如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...
2023/2/14 13:09:18

牛血清白蛋白(BSA)常見問題
牛血清白蛋白(BSA)常見問題:牛血清白蛋白(BSA)在實(shí)驗(yàn)室中是通用的,可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51



購物車 


